DENVER (KDVR) — A Colorado board created to review prescription drug prices is headed to court after it moved to limit the price of the arthritis drug Enbrel. Enbrel isn’t the only company the board is keeping an eye on.
Pharmaceutical company Amgen filed a federal lawsuit last week with the Colorado Prescription Drug Affordability Commission, which declared Enbrel unaffordable in February. Pharmaceutical companies argue that the measure is unconstitutional and violates commercial and patent laws.
Enbrel is not the first prescription drug to be subject to review, nor will it be the last. The committee also found that two of her other medications, an HIV drug, were not used. Genboya and cystic fibrosis drugs. Torikafta — It wasn’t out of reach. Next to be considered are Cosentyx for psoriasis and Stelara for Crohn’s disease.
What other drugs might be examined under the microscope next?
Top 20 Drugs on the Colorado Drug Affordability Commission List
of the board The latest report in October lists 604 types of medicines. Affordable and subject to review. Approximately 244 were prioritized on a weighted scale based on patient volume, changes in wholesale acquisition costs, patient out-of-pocket costs, total annual payments and average payments per person.
The list is also not legally binding, but rather “a tool to present data and spark discussion.” According to the board.
here it is Top 20 listed:
| brand name | strength | Dosage form | Patient copayment amount |
| humira | 40mg/0.4mL | pen injector kit | $2,982 |
| Torikafta | 100 mg-50 mg-75 mg (day)/150 mg (night) | tablet sequential | $1,732 |
| Enbrel | 50mg/mL(1mL) | pen type injector | $2,812 |
| Stellara | 90mg/mL | Syringe | $1,399 |
| humira | 40mg/0.4mL | syringe kit | $2,556 |
| Genboya | 150mg-150mg-200mg-10mg | Tablet | $1,293 |
| Overgio | 14mg | Tablet | $4,207 |
| Gilenya | 0.5mg | capsule | $3,367 |
| Standi | 40mg | capsule | $3,078 |
| Revlimid | 10mg | capsule | $3,232 |
| Imbruvica | 420mg | Tablet | $3,308 |
| enbrel | 50mg/mL(1mL) | Syringe | $2,709 |
| cosentics | 150mg/mL | pen type injector | $2,168 |
| Takuziro | 300mg/2mL (150mg/mL) | bottle | $4,999 |
| Ibrance | 125mg | Tablet | $1,862 |
| Opdivo | 240mg/24mL | bottle | $1,001 |
| norditropin | 15mg/1.5mL (10mg/mL) | pen type injector | $3,398 |
| Entyvio | 300mg | bottle | $2,447 |
| Epclusa | 400mg～100mg | Tablet | $1,887 |
| op smit | 10mg | Tablet | $2,594 |
These are just the top 20 on our priority list, some of which are already under consideration. The complete list is Colorado Prescription Drug Affordability Commission Dashboard.
Can Colorado cap prescription drug prices?
Prescription Drug Affordability Committee Created in 2021 It is the agency that reviews prescription drugs and assesses their affordability for Coloradans, and it also has the legal authority to limit prices. But this Congress, lawmakers are considering legislation that would restrict prescription drugs with price caps.
Senate Bill 24-060 So-called “orphan drugs” will be exempted. These are drugs that are designated as such because they treat rare diseases or conditions that typically affect fewer than 200,000 people in the United States.
Supporters of the bill argue that it concerns a relatively small number of drugs for very rare conditions. Opponents worry that some of these drugs have multiple uses.
The bill passed a Senate committee and was debated three times. The next scheduled floor date is April 1st.
